Señales en vivo de ABIO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 may 2024 @ 16:00):

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases...

Stats
Volumen de hoy	33 584.00
Volumen promedio	1.48M
Capitalización de mercado	47.73M
EPS	$0 ( 2024-04-24 )
Próxima fecha de ganancias	( $0 ) 2024-07-19
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.83
ATR14	$0.0130 (0.40%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-30	Ma-weaver Jacob	Buy	6 000	Stock option (right to buy)
2024-01-30	Hove Anders D	Buy	6 000	Stock Option (right to buy)
2024-01-30	Mitchell Daniel J	Buy	6 000	Stock Option (right to buy)
2024-01-30	Flynn James P	Buy	6 000	Stock Option (right to buy)
2024-01-30	Conway Robert E	Buy	6 000	Stock Option (right to buy)

INSIDER POWER
98.26
Last 95 transactions
Buy: 2 938 848 \| Sell: 17 694 644

ARCA Biopharma Inc Correlación

10 Correlaciones Más Positivas
SCTL	0.977
LABP	0.957
MESO	0.952
MOTNU	0.943
NN	0.94
RMRM	0.933
VFF	0.932
STOK	0.928
AMRB	0.928
SMTC	0.927

10 Correlaciones Más Negativas
ATHN	-0.937
ARIZ	-0.926
AMD	-0.923
OSIS	-0.918
QQQM	-0.918
QQQ	-0.918
LULU	-0.916
CIFR	-0.916
CYN	-0.915
EZGO	-0.912

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ARCA Biopharma Inc Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-111 000 (0.00 %)
EPS:	$-0.370

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-111 000 (0.00 %)
EPS:	$-0.370

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-114 000 (0.00 %)
EPS:	$-0.640

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.390

Financial Reports:

No articles found.

ARCA Biopharma Inc

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.